EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Neuphoria Therapeutics Inc (NEUP) fair value: what the stock is really worth

As of Oct 16, 2026: fair value (intrinsic value) of Neuphoria Therapeutics Inc stock $3.39, price $3.30, upside +2.8%, quality 31 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US64136E1029

NT Neuphoria Therapeutics Inc logo Thin data Oct 3, 2026

Neuphoria Therapeutics Inc

NEUP · US

Low PriorityFair Value upside is limited and quality is weak.

The stock costs about what our calculation considers fair.

Fair value $3.39 · Fairly valued (+2.8%)
Mixed Growth (revenue 5y +4.8 %/yr in USD)
Mixed vs. peers (3/7)
Quality 31/100
Negative free cash flow
Narrow moat 15/100 · thin data
Thin data
⚠ Dilution
Watch Neuphoria Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$176.76 $2.29 Fair Value $3.39 Dec 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

58‑month range $2.29 – $176.76 · fair‑value band $3.13 – $3.66 · the $3.30 price screens below the $3.39 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Neuphoria Therapeutics in your weekly email

Every Wednesday you see whether Neuphoria Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.

Show moreShow less

Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder.

The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer.

In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders.

The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions.

The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Stock analysis

Neuphoria Therapeutics Inc (NEUP) currently trades at $3.30, while our model-based Fair Value estimate is $3.39, so the stock looks roughly fairly valued today (gap 2.8%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $5.68 per share, and 2 of the 3 models we run sit above the $3.30 price.

Bear case: the Asset-Based group reads lowest at $2.27, and 1 of the 3 models stay below the price. Data coverage for this calculation is low.

Scenario range: $3.13 (bear) to $3.66 (bull), the price of $3.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Neuphoria Therapeutics Inc reported revenue of $1.2M in FY2026 versus $383K in FY2022, a compound +32.3%/yr. Reported net income was −$13.5M in FY2026.

Key figures

Market cap $17.9M · P/S ratio 16.0 · EPS (TTM) $−3.06 · Return on equity −61.7% · Return on assets (EBIT) −63.5% · Operating margin −15.7% · Revenue (TTM) $1.2M · Free cash flow −$12.4B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 3%, NEUP screens richer than that median.

Fair Value models

Bear $3.13 Fair Value $3.39 Bull $3.66
Price $3.30 · Upside +2.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $4.06 $5.68 $8.94 71
EV/EBITDA $3.68 $3.99 $4.31 64
NCAV (Graham) $1.69 $2.27 $3.39 51
All 3 models by family
DCF Models
Owner Earnings $4.06 $5.68 $8.94 71
Multiples
EV/EBITDA $3.68 $3.99 $4.31 64
Asset-Based
NCAV (Graham) $1.69 $2.27 $3.39 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 17
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−92.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2021 (pandemic). Over 10 years: −13.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−965.2% (2021) → −835.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch NEUP, get fair value alerts →

Compare Neuphoria Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 603 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside +2.9% · Above median
Profitability
Return on assets −0.1% · Above median
Operating margin (12 months) −15.7% · Bottom 25%
Growth and dividend
Revenue growth 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (12 months) 15.21× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $746.54 $1,275 +71% vs NEUP
Vertex Pharmaceuticals Incorporated VRTX $510.08 $561.09 +10% vs NEUP
argenx SE ARGX $825.03 $907.53 +10% vs NEUP
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs NEUP
WuXi Biologics (Cayman) Inc 2269 HK$52.65 HK$57.92 +10% vs NEUP
CSL Limited CSL A$181.46 A$179.90 −1% vs NEUP
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs NEUP
BeOne Medicines AG ONC $354.47 $280.94 −21% vs NEUP
Celltrion, Inc 068270 180,400 KRW 74,519 KRW −59% vs NEUP
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs NEUP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, survivorship-adjusted Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neuphoria Therapeutics Inc · Fair Value
$3.39 +3%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Neuphoria Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/NEUP

Frequently asked questions

Is Neuphoria Therapeutics Inc (NEUP) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $3.39 versus a price of $3.30, about +3% upside (fairly valued).
What is the fair value of NEUP?
Our model-based fair value for Neuphoria Therapeutics Inc is $3.39 (as of Oct 3, 2026), built from audited fundamentals. The current price: $3.30.
What is the quality score of NEUP?
Neuphoria Therapeutics Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuphoria Therapeutics Inc (NEUP)?
Our model-based price target is the fair value of $3.39 (as of Oct 3, 2026) from 3 valuation models. Cautious scenario $3.13, optimistic scenario $3.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Neuphoria Therapeutics Inc stock forecast for 2026?
Our models put fair value at $3.39, about +3% upside versus a price of $3.30 (fairly valued). Cautious scenario $3.13, optimistic scenario $3.66. The calculation is refreshed regularly with new filings.
What is the revenue of Neuphoria Therapeutics Inc (NEUP)?
Neuphoria Therapeutics Inc reported trailing-twelve-month revenue of about $1.2M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Neuphoria Therapeutics Inc (NEUP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuphoria Therapeutics Inc it is $3.39 per share (as of Oct 3, 2026), against a price of $3.30. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Neuphoria Therapeutics Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, NEUP trades below its calculated fair value: price $3.30, fair value $3.39, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEUP?
No. The price is what the market pays today ($3.30); the fair value is what the company's own numbers justify ($3.39). For Neuphoria Therapeutics Inc the two are $0.0940 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuphoria Therapeutics Inc worth?
The market values Neuphoria Therapeutics Inc at about $17.9M (market capitalisation, as of Oct 3, 2026). Per share that is $3.30; our models calculate a fair value of $3.39 per share.
What do the bullish and bearish scenarios say about NEUP?
Our models span a range for Neuphoria Therapeutics Inc: cautious scenario $3.13, base $3.39, optimistic $3.66 per share (as of Oct 3, 2026, price $3.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neuphoria Therapeutics Inc (NEUP)?
Balance-sheet figures for Neuphoria Therapeutics Inc (as of Oct 3, 2026): return on equity −61.7%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is NEUP from its 52-week high?
Neuphoria Therapeutics Inc trades at $3.30, about 79% below its 52-week high of $15.52 and 2% above the low of $3.24 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of $3.39 is for.
Which stocks are comparable to Neuphoria Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuphoria Therapeutics Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $3.30, calculated fair value $3.39 (+3%), Quality Score 31/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEUP calculated?
We run Neuphoria Therapeutics Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.4 % above its aggregate fair value. Neuphoria Therapeutics Inc currently trades 3 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neuphoria Therapeutics Inc (NEUP)?
The closing price on Oct 16, 2026 was $3.30. Our model-based fair value is $3.39, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neuphoria Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Neuphoria Therapeutics Inc

How large is the market capitalisation of Neuphoria Therapeutics Inc (NEUP)?
The market capitalisation of Neuphoria Therapeutics Inc is $17.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neuphoria Therapeutics Inc (NEUP)?
The price-to-sales ratio of Neuphoria Therapeutics Inc is 16.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neuphoria Therapeutics Inc (NEUP)?
Earnings per share at Neuphoria Therapeutics Inc are $−3.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Neuphoria Therapeutics Inc (NEUP)?
The return on equity (ROE) of Neuphoria Therapeutics Inc is −61.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neuphoria Therapeutics Inc (NEUP)?
On an EBIT basis the return on assets of Neuphoria Therapeutics Inc is −63.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neuphoria Therapeutics Inc (NEUP)?
The operating margin of Neuphoria Therapeutics Inc is −15.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Neuphoria Therapeutics Inc (NEUP) generate?
The free cash flow of Neuphoria Therapeutics Inc is −$12.4B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neuphoria Therapeutics Inc (NEUP) hold?
Neuphoria Therapeutics Inc holds more cash than debt, $19.9B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Neuphoria Therapeutics Inc in the live analysis

One click puts Neuphoria Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.